Asia-Pacific Human Leukocyte Antigen (HLA) Typing for Transplant Market, By Products and Services (Reagents and Consumables, Instruments, Software and Services), Technology (Sequencing- Based Molecular Assays, Molecular Assay Technologies, Non- Molecular Assay Technologies), Transplant Type (Solid Organ Transplant, Haematopoietic Stem Cell Transplant), Application (Diagnostic Applications, Research Application), End User (Independent Reference Laboratories, Hospitals and Transplant Centres, Research Laboratories and Academic Institutes), Country (China, India, Japan, South Korea, Australia, Thailand, Malaysia, Philippines, Singapore, Indonesia, and Rest of Asia-Pacific) Industry Trends and Forecast to 2028.
Market Analysis and Insights: Asia-Pacific Human Leukocyte Antigen (HLA) Typing for Transplant Market
Asia-Pacific human leukocyte antigen (HLA) typing for transplant market is expected to gain significant growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the Asia-Pacific human leukocyte antigen (HLA) typing for transplant market is growing with a CAGR of 8.4% in the forecast period of 2021 to 2028 and is expected to reach USD 240.14 million by 2028 from USD 129.52 million in 2020. Rising demand for organ transplant procedures is acting as driver for the growth of the human leukocyte typing for transplant market.
Human leukocyte antigen (HLA) typing is used to match patients and donors for bone marrow or cord blood transplants. HLA are proteins -- or markers -- found on most cells in the body. The immune system uses these markers to recognize which cells belong to the body and which do not.
Research has found that a donor must match a minimum of 6 HLA markers. Several Many times a closer match is required. A best match is found through detailed testing. As some HLA types are more common than others, some patients may face a greater challenge in finding a matching donor. Some HLA types are found more often in certain racial and ethnic groups.
A close match between a donor’s and a patient’s HLA markers is essential for a successful transplant outcome. HLA matching promotes the growth and development of new healthy blood cells (called engraftment) and reduces the risk of a post-transplant complication called graft-versus-host (GVHD) disease.
The high demand of organ donation, increasing innovations and technologies and novel product launch are also propelling the growth of the Asia-Pacific human leukocyte antigen (HLA) typing for transplant market.
A growing number of people are affected with by the HLA disorders which demand highly effective and advanced treatment to minimize the risk during the treatment. The healthcare systems need highly advanced drugs for numerous different types of HLA disorders during the treatment of patients. Therefore, the major market players are highly focusing on product launches and product approvals. Additionally, the government and regulatory bodies are supporting market players by virtue of product approval.
Rising product launches is acting as an opportunity for this market and is expected to impel the market growth for boosting the demand of global human leukocyte typing for transplant market.
Research on the human leukocyte antigen (HLA), is an extensively studied molecule involved in immunity and NGS technologies have revolutionised HLA typing procedure by providing fast and cost-effective technology. It is expected that lack skilled professionals is the major key challenge for the future growth of global human leukocyte antigen (HLA) typing for transplant market.
Asia-Pacific human leukocyte antigen (HLA) typing for transplant market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Asia-Pacific Human Leukocyte Antigen (HLA) Typing for Transplant Market and Market Size
Asia-Pacific human leukocyte antigen (HLA) typing for transplant market is segmented on the basis of products and services, technology, transplant type, application, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of by products and services, Asia-Pacific human leukocyte antigen (HLA) typing for transplant market is segmented in reagents and consumables, instruments, software and services. In 2021, instruments segment is expected to dominate the market due to rising healthcare expenditure.
- On the basis of technology, Asia-Pacific human leukocyte antigen (HLA) typing for transplant market is molecular assay technologies and non- molecular assay technologies. In 2021, molecular assay technologies segment is expected to dominate the market because of the rising success and greater improvement in post-transplant outcome.
- On the basis of transplant type, Asia-Pacific human leukocyte antigen (HLA) typing for transplant market is segmented solid organ transplant and haematopoietic stem cell transplant. In 2021, solid organ transplant segment is expected to dominate the market due to better patient compliance.
- On the basis of application, the Asia-Pacific human leukocyte antigen (HLA) typing for transplant market is segmented into diagnostic applications and research application. In 2021, diagnostic applications segment is expected to dominate the market because of the increased incidence of vital organ failure, doctors tend to detect problem prior via diagnostic applications.
- On the basis of end user, the Asia-Pacific human leukocyte antigen (HLA) typing for transplant market is segmented into independent reference laboratories, hospitals and transplant centres, research laboratories and academic institutes. In 2021, hospitals & transplant centers segment is expected to dominate the market owing to increased government funding.
Asia-Pacific Human Leukocyte Antigen (HLA) Typing for Transplant Market Country Level Analysis
The Asia-Pacific human leukocyte antigen (HLA) typing for transplant market is analyzed and market size information is provided based on country, products and services, technology, transplant type, application, and end user.
Countries covered in the Asia-Pacific human leukocyte antigen (HLA) typing for transplant market report are Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, and rest of Asia-Pacific.
China is expected to dominate the Asia-Pacific human leukocyte antigen (HLA) typing for transplant market due to increasing rising government funding in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Rising Healthcare Expenditure and Escalation in Innovations and Technologies in the Asia-Pacific Human Leukocyte Antigen (HLA) Typing for Transplant Market are Creating New Opportunities for Players in the Asia-Pacific Human Leukocyte Antigen (HLA) Typing for Transplant Market
Asia-Pacific human leukocyte antigen (HLA) typing for transplant market also provides you with detailed market analysis for every country growth in particular industry with the Asia-Pacific human leukocyte antigen (HLA) typing for transplant market sales, impact of advancement in the Asia-Pacific human leukocyte antigen (HLA) typing for transplant market and changes in regulatory scenarios with their support for the Asia-Pacific human leukocyte antigen (HLA) typing for transplant market in the period of 2011-2019.
Competitive Landscape and Asia-Pacific Human Leukocyte Antigen (HLA) Typing for Transplant Market Share Analysis
Asia-Pacific human leukocyte antigen (HLA) typing for transplant market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, and technology lifeline curve. The above data points provided are only related to the companies’ focus related to Asia-Pacific human leukocyte antigen (HLA) typing for transplant market.
Major players covered in the report are Thermo Fisher Scientific Inc., Illumina, Inc., Luminex Corporation, QIAGEN, CareDX, Inc., Immucor Inc., Bio Rad Labaratories, Inc., Takara Bio Inc., BD, Fujirebio, TBG Diagnostics Limited, and GenDx.
DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many product launches and agreements are also initiated by the companies worldwide, which are further accelerating the Asia-Pacific human leukocyte antigen (HLA) typing for transplant market.
For instance,
- In October 2017, TBG's HLAssure SE SBT Kits received the China CFDA approval for clinical use. This is the first approval for a High Resolution HLA Typing Kit in China. This helped the company to strengthened its footprint in China and boosted market growth
SKU-